Ocular Therapeutix
OCUL
70 hedge funds and large institutions have $309M invested in Ocular Therapeutix in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 7 reducing their positions, and 16 closing their positions.
414% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 7
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
1% less funds holding
Funds holding: 71 → 70 (-1)
19% less capital invested
Capital invested by funds: $380M → $309M (-$71.1M)
20% less call options, than puts
Call options by funds: $650K | Put options by funds: $814K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$44.5M |
| 2 |
LCP
Lamond Capital Partners
San Francisco,
California
|
+$10.5M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$7.43M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.21M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$6.22M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.37M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.96M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$1.42M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.41M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EMG
76
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$590K | -28,068 | Closed |
|
|
RCM
77
Rotella Capital Management
Bellevue,
Washington
| – | -$388K | -18,461 | Closed |
|
78
Citadel Advisors
Miami,
Florida
| – | -$372K | -17,682 | Closed |
|
79
Tudor Investment Corp
Stamford,
Connecticut
| – | -$371K | -17,663 | Closed |
|
80
Goldman Sachs
New York
| – | -$273K | -12,993 | Closed |
|
|
GCP
81
GSA Capital Partners
London,
United Kingdom
| – | -$261K | -12,412 | Closed |
|
82
Renaissance Technologies
New York
| – | -$231K | -10,992 | Closed |
|
83
LPL Financial
San Diego,
California
| – | -$226K | -10,700 | Closed |
|
|
TC
84
TFS Capital
West Chester,
Pennsylvania
| – | -$217K | -10,330 | Closed |
|
85
Invesco
Atlanta,
Georgia
| – | -$58K | -2,767 | Closed |
|
86
Citigroup
New York
| – | -$3.34K | -166 | -98% |
|
OCUL Hedge Fund Activity: Q3 2015 in Review
70 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2015, worth a combined $309M — down 19% from $380M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of OCUL and 15 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 36 added.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $44.5M. The largest seller was Pentwater Capital Management, exiting entirely with an estimated $6.22M sold.
- 70 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2015, down from 71 in Q2 2015.
- Funds reported $309M of Ocular Therapeutix stock for Q3 2015, down 19% quarter-over-quarter.
- 15 funds opened new Ocular Therapeutix positions in Q3 2015 and 16 closed out, a net change of -1 holder.
- The largest Ocular Therapeutix buyer in Q3 2015 was Versant Venture Management, an estimated $44.5M added.
- The largest Ocular Therapeutix seller in Q3 2015 was Pentwater Capital Management, an estimated $6.22M sold.
Based on aggregated 13F filings for Q3 2015.